Company profile
ORAGENICS INC
AMEX:OGENBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06870240 | phase2 | not_yet_recruiting | 2025-06-01 | 2026-01-01 | Oragenics, Inc. | A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury |
| NCT03234465 | phase2 | terminated | 2017-07-18 | 2020-03-31 | Oragenics, Inc. | Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day |
FDA applications (0)
No records yet.